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Abstract 
The practice of phage therapy, which uses bacterial 
viruses (phages) to treat bacterial infections, has been 
around for almost a century. The universal decline in 
the effectiveness of antibiotics has generated renewed 
interest in revisiting this practice. Conventionally, phage 
therapy relies on the use of naturally-occurring phages 
to infect and lyse bacteria at the site of infection. 
Biotechnological advances have further expanded the 
repertoire of potential phage therapeutics to include novel 
strategies using bioengineered phages and purified phage 
lytic proteins. Current research on the use of phages 
and their lytic proteins, specifically against multidrug-
resistant bacterial infections, suggests phage therapy 
has the potential to be used as either an alternative 
or a supplement to antibiotic treatments. Antibacterial 
therapies, whether phage- or antibiotic-based, each have 
relative advantages and disadvantages; accordingly, 
many considerations must be taken into account when 
designing novel therapeutic approaches for preventing 
and treating bacterial infections. Although much is still 
unknown about the interactions between phage, bacteria, 
and human host, the time to take phage therapy seriously 
seems to be rapidly approaching. 
Key words: Bacteriophage; Bacteriophage therapy; Phage; 
Phage therapy; Endolysin; Lysin; Multidrug resistance; 
Antibiotic resistance; Phage safety; Methicillin-resistant 
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Core tip: Phage therapy is widely being reconsidered as 
an alternative to antibiotics. The use of naturally-occurring 
phages to treat bacterial infection has a contentious 
history in western medicine. However, the emergent 
landscape of phage-based antimicrobials has advanced 
well beyond traditional methods. In this rapidly evolving 
field, novel technologies such as bioengineered chimeras 
of phage-derived lytic proteins show potential as a new 
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class of antibacterial pharmaceuticals. This review aims to 
provide a topical perspective on the historical context of 
phage therapy, in order to highlight modern advances in 
phage research and innovations in the field. 
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INTRODUCTION 
Almost a decade before the discovery of penicillin, 
the controversial practice of phage therapy was being 
developed as a treatment for bacterial infections. 
Phages, short for bacteriophages, are bacteria-specific 
viruses that have been used as a treatment against 
pathogens such as Shigella dysenteriae as early as 
1919[1]. With an estimated 1031-1032 phages in the 
world at any given time[2], they make up the most 
abundant biological entity on Earth and play a crucial 
role in regulating bacterial populations; phages are 
responsible for the death of approximately 20%-40% 
of all marine surface bacteria every 24 h[3]. Much of 
the controversy surrounding phage therapy was due to 
poor documentation of use and variable success. The 
complications in implementing phage therapy stemmed 
from how little was known about phages at the time 
of their discovery. In fact, the nature of their existence 
was a topic of contention until they were visualized in 
the 1940’s after the invention of electron microscopy[4]. 
A number of logistical and technical obstacles in 
developing phage therapy led to its widespread 
abandonment after the discovery of antibiotics. 
The advent of pharmaceutical antibiotics in the 
mid-20th century, along with a better understanding 
of disease and sanitation, revolutionized healthcare 
and drastically improved both quality of life and life 
expectancy in the industrialized world. In 1900, life 
expectancy for men and women in the United States 
was 46 and 48, respectively, and the major causes of 
death were infectious diseases, many of which were 
bacterial (e.g., cholera, diphtheria, typhoid fever, 
plague, tuberculosis, typhus, scarlet fever, pertussis, 
and syphilis)[5]. Antibiotics helped usher in a new era in 
medicine, rapidly becoming an indispensable medical 
tool with 262.5 million treatment courses prescribed 
in the United States in 2011 alone (842 prescriptions 
per 1000 persons) and an estimated 100000-200000 
tons of antibiotics used globally between medicine, 
agriculture, and horticulture each year[6,7]. Antibiotic 
resistance genes encoding for bacterial resistance 
to common antibiotics, including β-lactams, ami-
noglycosides, chloramphenicols, and tetracycline, are 
posing a major threat to current medical treatment 
of common diseases, and these genes now appear 
to be abundant in the environment[8]. The spread of 
antibiotic resistance genes carries a unique danger in 
that many antibiotics have diminishing efficacy against 
common infections, particularly the difficult-to-treat 
nosocomial infections caused by the ESKAPE pathogens 
(Enterococcus faecium, Staphylococcus aureus, Kle­
bsiella pneumoniae, Acinetobacter baumannii, Pseu­
domonas aeruginosa, and Enterobacter spp.). 
Admonitions of a return to “the pre-antibiotic era” 
have become increasingly common and regulatory 
organizations such as the Centers for Disease Control 
(CDC) and WHO have declared antibiotic resistance 
a threat to global health[9,10]. The CDC estimates anti-
biotic-resistant infections result in 2 million illnesses 
and at least 23000 deaths a year, with many more 
dying from conditions complicated by antibioticre-
sistant infections, costing the United States $55 
billion annually[7]. According to the United Kingdom 
government’s 2016 Review on Antimicrobial Resistance, 
an estimated 700000 people die each year globally 
from resistant infections with a projected cost of $100 
trillion and a death toll of 10 million by 2050[7]. In the 
United States, methicillin-resistant S. aureus (MRSA) 
infections alone account for more deaths than HIV/AIDS 
and tuberculosis combined[11]. Since the discovery of 
antibiotics, there has been a steady stream of novel 
antibacterial pharmaceuticals in what has been dubbed 
the “antibiotic pipeline”. However, due to the rate at 
which bacteria evolve resistance to antibiotics, there 
has been less commercial interest in the research 
and development of novel compounds. In the years 
of 1983-1987, there were 16 new pharmaceutical 
antibiotics approved by the Food and Drug Admini-
stration (FDA) for use in the United States, this num-
ber has steadily trended downwards and between 
2010-2016 only 6 new antibiotics were approved[12]. At 
the end of the antibiotic pipeline is the carbapenem class 
of antibiotics, often reserved as the “last resort” due to 
their adverse effects on health. Beginning in 2000, the 
incidence of carbapenem-resistant, hospital-acquired K. 
pneumoniae infections began to increase in the United 
States; due to the lack of treatment options, these 
infections are associated with a 40%-50% mortality 
rate[13]. Reaching the end of the antibiotic pipeline could 
signal a shift in the global culture of infectious disease 
treatment and some claim is the imminent return to a 
pre-antibiotic era of medicine. 
On September 21, 2016, the United Nations General 
Assembly convened to discuss the problem of antibiotic 
resistance and deemed it “the greatest and most urgent 
global risk”[14]. In the hunt for alternative strategies 
for prophylaxis and control of bacterial infection, one 
of the more popular suggestions involves revisiting 
the practice of phage therapy. Proponents of phage 
therapy tout several major advantages that phages 
have over antibiotics such as host-specificity, self-
amplification, biofilm degradation, and low toxicity to 
humans[15,16]. Owing to the development of analytical 
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tools capable of studying these small biological entities 
(approximately 25-200 nm in length), such as next-
generation sequencing and electron microscopy, the 
field of phage biology is only now reaching maturity. 
These technological advancements have ushered in 
a renaissance of phage therapy research as indicated 
by a wave of recent human clinical trials and animal 
research. To fully evaluate the viability of phage therapy, 
one must also consider the role of the indigenous gut 
phageome in human health and disease. However, this 
complex story is only beginning to unfold and will not be 
included in this review (for current literature review see 
Wahida, Ritter and Horz[17] 2016). This review aims at 
discussing historical use of phage therapy and current 
research on the feasibility of phage-based infection 
control with a focus on multidrug-resistant infections. 
PHAGE BIOLOGY BASICS 
Phages are simple, yet incredibly diverse, non-living 
biological entities consisting of DNA or RNA enclosed 
within a protein capsid. As naturally-occurring bacterial 
parasites, phages are incapable of reproducing inde-
pendently (i.e., non-living) and are ultimately dependent 
on a bacterial host for survival. Phages typically bind 
to specific receptors on the bacterial cell surface, inject 
their genetic material into the host cell, and then either 
integrate this material into the bacterial genome (so-
called “temperate” phages) and reproduce vertically from 
mother to daughter cell, or hijack the bacterial replication 
machinery to produce the next generation of phage 
progeny and lyse the cell (so-called “lytic” phages). Upon 
reaching a critical mass of phage progeny, which can 
be anywhere from a few to over 1000 viral particles, 
depending on environmental factors, the lytic proteins 
become active and hydrolyze the peptidoglycan cell wall, 
releasing novel phage to reinitiate the lytic cycle[18,19]. 
Most phages are infectious only to the bacteria 
that carry their complementary receptor, which 
effectively determines lytic phage host range[20]. Host 
specificity varies among phages, some of which are 
strain-specific, whereas others have demonstrated 
the capability of infection across a range of bacterial 
strains and even genera[21,22]. Bacteria have evolved 
numerous mechanisms to resist infection by lytic pha-
ges, and phages have an equally impressive diversity of 
mechanisms for breaking this resistance. For bacteria, 
this can include alteration or loss of receptors and 
integration of phage DNA into the clustered regularly 
interspaced palindromic repeats/CRISPR associated 
system (CRISPR/Cas) system[23], while for phage this 
can include recognition of new or altered receptors 
and anti-CRISPR genes[24]. The most common lytic 
phages associated with human pathogens and the gut 
microbiota are in the orders Caudovirales, commonly 
known as “tailed phages” which contain double-
stranded DNA genomes, and Microviridae, which are 
tailless, single-stranded DNA viruses[25,26]. 
In contrast to lytic phages, lysogenic phages 
integrate their genetic material into the bacterial 
chromosome in the form of an endogenous prophage 
(less commonly phage DNA can remain separate as a 
plasmid but still be stably transmitted across bacterial 
generations). The bacterial lysogen then propagates 
the prophage with each cell division. Environmental 
stressors on the bacterial host are capable of inducing 
the lysogenic phage from the latent prophage form, 
triggering a transition to the lytic cycle and the 
release of phage progeny into the environment. When 
incorporating their genetic material into the bacterial 
genome, prophage-encoded genes become available 
for transcription by the host. Up to 18 prophages have 
been found in one bacterial genome, as in the food 
pathogen Escherichia coli (E. coli) O157:H7 strain 
Sakai[27], with prophage-encoded genes comprising up 
to 20% of bacterial chromosomal content[28]. Prophage 
genes can be beneficial to the bacterial host and can 
encode for virulence factors (e.g., diphtheria toxin, 
shiga toxin, and botulinum toxin), metabolic genes, and 
antibiotic resistance genes (e.g., β-lactamases)[29-32]. 
Phage biologists now recognize that phage lifecycles 
can fall on a spectrum between lytic and lysogenic 
with pseudolysogenic, chronic, and cryptic lifecycles as 
examples of recent classifications[19,33]. Conventional 
phage therapy relies on strictly lytic phages, which 
obligately kill their bacterial host. For treatment, lytic 
phages are compiled into preparations called “phage 
cocktails” which consist of multiple phages proven to 
have in vitro efficacy against the target pathogen. 
HISTORY OF PHAGE THERAPY 
Although the idea of using bacterial viruses thera-
peutically against bacterial infections has recently gained 
traction in response to the emergence of multidrug-
resistant pathogens, the practice has been around for 
nearly a century. Since the initial observations of phage-
induced bacterial lysis, the biological nature of phage, as 
well as their therapeutic value, has been controversial. 
Frederick Twort first described the characteristic zone 
of lysis associated with phage infection in 1915, but 
it was Felix d’Herelle who identified the source of this 
phenomenon, attributed the plaques to bacterial viruses, 
and coined the term “bacteriophage” (literally “bacteria-
eater”). It was also d’Herelle who conceived of the idea 
to use phages therapeutically and is responsible for 
the first documented clinical use of phage in 1919 at 
the Hôpital des Enfants-Malades in Paris where phages 
were successfully used to treat 4 pediatric cases of 
bacterial dysentery[1]. Despite several successful trials, 
d’Herelle’s early experiments were notorious for being 
poorly controlled and his research was vigorously 
disputed[3]. Nevertheless, d’Herelle continued to pioneer 
phage therapy with the treatment of dysentery, cholera, 
and the bubonic plague in the early 20th century with a 
series of phage therapy centers and commercial phage 
production plants throughout Europe and India[34]. One 
1931 trial of phage therapy as a treatment for cholera 
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P. aeruginosa[43]. Phage cocktails have also been used 
to treat antibiotic-resistant P. aeruginosa infections 
of the skin, lungs, and gastrointestinal tract in animal 
models[38,44]. Additional animal studies show similarly 
promising results for multidrug-resistant E. coli O25:H4-
ST131[45], Vibrio parahaemolyticus[46], S. aureus[44,47], and 
A. baumanii[38]. There is even an indication that phage 
are capable of restoring antibiotic sensitivity in antibiotic-
resistant bacteria, as in the case of multidrug-resistant P. 
aeruginosa[48]. 
Human trials for phage therapy have taken place for 
almost a century at several institutes in Eastern Europe, 
the most famous of which are the Eliava Institute of 
Bacteriophage and the Institute of Immunology and 
Experimental Therapy in Wroclaw, Poland. The Eliava 
Institute has extensively used phage in preclinical and 
clinical treatment of common bacterial pathogens such 
as S. aureus, E. coli, Streptococcus spp., P. aeruginosa, 
Proteus spp., S. dysenteriae, Salmonella spp., and 
Enterococcus spp.[49]. Effective applications range from 
surgical to gastroenterological, both therapeutic and 
prophylactic. In a six patient case series of antibiotic-
unresponsive diabetic foot ulcers, topical application of 
S. aureus-specific phage was sufficient for recovery in 
all individuals[50]. In a 1938 clinical trial, 219 patients 
with bacterial dysentery (138 children and 81 adults) 
were treated solely with a phage cocktail consisting of 
a variety of phage targeting Shigella flexneri, Shigella 
shiga, E. coli, Proteus spp., P. aeruginosa, Salmonella 
typhi, Salmonella paratyphi A and B, Staphylococcus 
spp., Streptococcus spp. and Enterococcus spp.; cock-
tails were administered both orally and rectally. Within 
24 h, 28% of patients with blood in their stools were 
relieved of this symptom, with a further 27% showing 
improvement within 2-3 d. Overall, 74% of the 219 
patients showed improvement or were completely 
relieved of symptoms[51]. Additionally, during a 1974 
typhoid epidemic, a cohort of 18577 children was 
enrolled in a prophylactic intervention trial using typhoid 
phages. Phage administration resulted in a 5-fold 
decrease in typhoid incidence compared to placebo[49]. 
The potential for phage therapy has yet to be fully 
realized since phages tend to be more effective against 
the target pathogen when used in combination with 
antibiotics[52], a treatment option that has not yet been 
investigated in humans. 
Currently there are no phage therapy products 
approved for human use in the EU or United States. How-
ever, in the food industry, there are several commercial 
phage preparations used for biocontrol of bacterial 
pathogens that are approved by the FDA under the 
classification of “generally considered as safe.” These 
preparations are used against Salmonella spp., Listeria 
monocytogenes, MRSA, E. coli O157:H7, Mycobacterium 
tuberculosis, Campylobacter spp., and Pseudomonas 
syringae, among others[53-56]. Phages also have potential 
value for pathogen detection, an example of which is 
using bioluminescent reporter phage to detect Bacillus 
in the Punjab region of India involved a cohort of 118 
control subjects and 73 experimental subjects who 
received phage treatment; d’Herelle observed a 90% 
reduction in mortality with 74 lethal outcomes in the 
control group and only 5 in the experimental group[1]. 
Along with d’Herelle, several other entrepreneurs 
attempted to commercialize phage production in 
Brazil and the United States with phage preparations 
for Staphylococcus, Streptococcus, E. coli, and other 
bacterial pathogens[34]. These preparations were shipped 
throughout the world to willing clinicians but treatment 
was met with mixed success; this lack of reliability, in 
large part, added to the preference for antibiotics in 
western medicine[1]. 
Many mistakes were made during these early trials 
of phage therapy and most can be attributed to a 
poor understanding of the biological nature of phages. 
Rudimentary purification and storage protocols resulted 
in low titers of active phage and contamination from 
bacterial antigens, and phages that lacked infectivity 
for the target bacteria were used for treatment. 
Furthermore, delivery of phage to the site of infection 
was confounded by the medical limitations of the day. 
For example, the role of the patient’s innate immune 
response in removing active phage and diminishing the 
efficacy of phage therapy was only observed recently as 
a potentially confounding physiological mechanism[35]. 
As a result, phage therapy was widely dismissed by 
most of western medicine after the introduction of 
pharmaceutical antibiotics in the 1940’s. The exception 
to this is in the former Soviet Union and Eastern Europe 
where clinical phage therapy has been used extensively 
to treat antibiotic-resistant infections caused by a 
range of infectious bacteria such as Staphylococcus, 
Pseudomonas, Klebsiella, and E. coli[36,37]. 
PHAGE AGAINST CLINICALLY 
SIGNIFICANT PATHOGENS 
Recent investigations using animal models have explored 
phage treatment against a range of clinically significant 
pathogens. When challenged with gut-derived sepsis 
due to P. aeruginosa, oral administration of phage saved 
66.7% of mice from mortality compared to 0% in the 
control group[38]. In a hamster model of Clostridium 
difficile (C. difficile)-induced ileocecitis, a single dose of 
phage concurrent with C. difficile administration was 
sufficient prophylaxis against infection; phage treatments 
post-infection saved 11 of 12 mice whereas control 
animals receiving C. difficile and clindamycin died within 
96 h[39]. Phage combinations also significantly reduced 
C. difficile growth in vitro and limited proliferation 
in vivo using a hamster model[40]. Intraperitoneal 
administration of a single phage strain was sufficient 
to rescue 100% of mice in bacteremia models using 
vancomycin-resistant E. faecium[41], extended spectrum 
β-lactamase producing E. coli[42], and imipenem-resistant 
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DEVELOPMENT AND APPLICATION OF 
PHAGE-DERIVED LYTIC PROTEINS 
Among the most promising of advances in phage 
therapy is the isolation of phage-encoded lytic enzymes, 
which are functionally similar to the antimicrobial 
eukaryotic enzyme lysozyme. Genes for phage lytic 
enzymes are expressed by the bacterial host during 
the lytic cycle and assist the phage by hydrolyzing the 
cell wall to release viral progeny. The discovery and 
analysis of these proteins opens the possibility for the 
development of novel phage-based pharmaceuticals. 
Two major protein classes are employed by the 
majority of phage species during the lysis of the ba-
cterial host. One of which is the transmembrane 
protein holin and the other is a peptidoglycan cell wall 
hydrolase called endolysin (lysin). These two proteins 
work together in triggering the lysis of the bacterial cell. 
The holin protein acts as a molecular “clock” in the lytic 
cycle. During the process of viral assembly within the 
cytoplasm, holin molecules accrue in the cell membrane. 
At the end of the lytic cycle the holin proteins trigger an 
opening on the cytoplasmic side of the cell membrane, 
allowing the lysin proteins to access and hydrolyze the 
cell wall[63]. Although both of these enzymes are present 
across the majority of phage species, there is huge 
anthracis[56]. In 2011 there was an estimated 48 million 
cases of food poisoning in the United States alone[55]. 
Evidence suggests that phage biocontrol can be an 
effective method for improving food safety at numerous 
stages in meat production and processing, and also has 
potential to reduce bacterial contamination in fruits, 
vegetables, and dairy products[55]. These investigations 
into phage biocontrol in food production, as well as recent 
placebo-controlled human trials that demonstrated the 
safety of oral phage administration[57-60], are gradually 
beginning to fill the knowledge gap in phage therapy 
safety. The evidence on phage safety will continue to 
strengthen with further randomized, double-blind, and 
placebo-controlled phase Ⅰ/Ⅱ clinical trials of phage 
therapy, such as the one that established both safety 
and efficacy in treating chronic otitis caused by antibiotic-
resistant P. aeruginosa[61]. 
Innovations in the gene editing tool CRISPR/Cas 
have created novel opportunities for phage therapy. One 
example of which is the use of bioengineered phage to 
deliver a CRISPR/Cas programmed to disrupt antibiotic 
resistance genes and destroy antibiotic resistance 
plasmids[62]. These phages may be applied to hospital 
surfaces to reduce frequency and spread of antibiotic 
resistance genes. The field of bioengineered phages 
is still in its infancy but will undoubtedly yield many 
invaluable technologies such as this (Table 1). 
Table 1  Published findings on phage therapy in humans and in animal models
Causative agent Model Condition Oral Result summary1 Ref.
Shigella dysenteriae Human Dysentery Oral All four treated individuals recovered after 24 h [1]
Vibrio cholerae Human Cholera Oral 68 of 73 survived in treatment group and only 44 of 118 
in control group
[1]
Pseudomonas aeruginosa Murine Sepsis Oral 66.7% reduced mortality [38]
Clostridium difficile Hamster Ileocecitis Oral Co-administration with C. difficile prevented infection [39]
Hamster Ileocecitis Oral dose every 8 h 
for 72 h
92% reduced mortality [39]
Vancomycin-resistant Enterococcus 
faecium
Murine Bacteremia i.p. 100% reduced mortality [41]
β -lactamase producing Escherichia coli Murine Bacteremia i.p. 100% reduced mortality [42]
Imipenem-
resistant P. aeruginosa
Murine Bacteremia i.p. 100% reduced mortality [43]
Acinetobacter baumannii, P. 
aeruginosa and Staphylococcus aureus
Murine Sepsis i.p. Animals protected against fatal dose of A. baumannii 
and P. aeruginosa but not S. aureus
[44]
Escherichia coli Murine Meningitis 
and Sepsis
i.p. or s.c. 100% and 50% reduced mortality for meningitis and 
sepsis, respectively
[45]
MDR Vibrio parahaemolyticus Murine Sepsis i.p. and oral 92% and 84% reduced mortality for i.p. and oral routes, 
respectively
[46]
S. aureus Rabbit Wound 
infection
s.c. Co-administration with S. aureus prevented infection [47]
MDR S. aureus Human Diabetic foot 
ulcer
Topical All 6 treated patients recovered [50]
Unclassified bacterial dysentery Human Dysentery Oral Phage cocktail improved symptoms of 74% of 219 
patients
[51]
Salmonella typhi Human Typhoid Oral In cohort of 18577 children, phage treatment associated 
with 5-fold decrease in typhoid incidence compared to 
placebo
[49]
Antibiotic-resistant P. aeruginosa Human Chronic Otitis Oral Phage treatment safe and symptoms improved in 
double-blind, placebo-controlled Phase I/II trial
[61]
1Reduced mortality is for phage-treated groups and are relative to 100% mortality in control animals, unless otherwise specified. MDR: Multi-drug-
resistant; i.p.: Intraperitoneal injection; s.c.: Subcutaneous injection.
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negative pathogens, several researchers have begun to 
bioengineer artificial lysin molecules, termed Artilysins, 
that are capable of penetrating the outer membrane. 
Some of these lysins are created by combining the 
active site of the lysin enzyme with lipopolysaccharide-
destabilizing peptides which allows the molecule to 
penetrate the outer membrane. So far Artilysins have 
been shown to decolonize P. aeruginosa in a nematode 
gut model and protect human keratinocytes when 
challenged with A. baumannii[76].
Adding to the appeal of lysins as antibacterial 
agents, it is widely considered to be unlikely that 
bacteria will evolve resistance to lysins due to the fact 
that they target sites on the peptidoglycan cell wall 
critical for bacterial viability[63]. Engineered recombinant 
phage lytic proteins would be far easier to mass produce 
and administer than preparations of actual phage, 
which can be limited by a short shelf life, removal by 
the reticuloendothelial system of the host, and the 
potential for generating neutralizing antibodies[35]. 
Future potential for phage lysin application includes 
combination therapy of lysins in conjunction with 
antibiotics, which has been shown to be more effective 
than antibiotics or lysins alone against pathogens such 
as MRSA and C. difficile in mice[77-79] (Table 2). 
PHAGE THERAPY VS ANTIBIOTIC 
THERAPY 
Both antibiotics and phages function as antibacterials 
that disrupt bacterial colonies through lysis or inhibition, 
yet several key differences make each antibacterial 
more or less appropriate depending on the situation. 
Safety 
Adverse reactions to antibiotics are well documented 
and include instances of anaphylaxis, nephrotoxicity, 
cardiotoxicity, hepatotoxicity, and neurotoxicity, as 
well as a number of gastrointestinal and hematological 
complications[80]. The majority of adverse reactions are 
allergic reactions; in these rare instances the anaphylaxis 
is associated with specific classes of antibiotics or is the 
product of high tissue concentrations[81-83]. In contrast 
to the comprehensive literature on antibiotic safety, 
phage therapy has only recently gained attention 
by western medicine and, as a result, much of the 
available information on phage safety is new. Although 
oral phage administration is generally considered to 
be safe[57-60], a major consideration for phage therapy 
is the translocation of phage across the intestinal 
epithelium where they subsequently circulate within 
the blood[84]. Some data show that phage translocation 
may benefit the host by downregulating the immune 
response to indigenous gut microbe antigens through 
the inhibition of interleukin-2, tumor necrosis factor, 
and interferon gamma production[84]. Other studies 
discovered a host innate immune response aimed at 
removing phage after administration in mice[35,85]. While 
structural and biochemical variability and therefore little 
sequence conservation between phage species. Each 
phage can encode for several unique lysin and holin 
enzymes, some of which are highly specific but others 
can exhibit broad-spectrum activity between strains 
and even between species, as in the case of recently 
discovered lysin ABgp46. ABgp46 has the ability to 
lyse several gram-negative and multidrug-resistant 
pathogens, including A. baumannii, P. aeruginosa, and 
Salmonella typhimurium[64]. 
Phage lysins alone are capable of bacterial cell lysis, 
whereas holins are not; therefore lysins have received 
a lot of attention as potential antimicrobial agents. 
These proteins are fast acting, potent, and inactive 
against eukaryotic cells. Lysins have successfully saved 
mice from bacteremia caused by multidrug-resistant 
A. baumannii[65], Streptococcus pneumoniae[66], and 
MRSA[67], among others[63]. Combining phage lysins and 
antibiotics may be more effective at eliminating infections 
than by using antibiotics alone, as demonstrated in vitro 
and ex vivo in a colon model using C. difficile.[68]. Not 
all lysins show equal therapeutic potential, however, as 
demonstrated by Gilmer et al[69] who identified a uniquely 
potent lysin, PlySs2, which was highly effective against a 
range of pathogenic Streptococcus and Staphylococcus 
species, including MRSA, and was fully functional after 10 
freeze-thaws. A single dose administered intraperitoneally 
to mice in a mixed S. pyogenes and MRSA bacteremia 
model provided a significantly higher survival rate than 
treatment with 3 previously characterized lysins[69]. A 
recent study exploring the isolation and application of 
phage proteins has revealed that lysins are even capable 
of crossing epithelial cell membranes to eliminate difficult 
to treat intracellular infections of S. pyogenes[70]. Phage 
lysins can also disrupt vegetative cells as demonstrated 
with the B. anthracis lysin PlyG which is capable of 
attacking endospores of bacillus, a distinct advantage 
over antibiotics[71]. Lysins can also be mass produced 
through common recombinant techniques. The gene 
for bacteriophage-derived cysteine, histidine-dependent 
amido hydrolase/peptidase (CHAPK) has been cloned 
and inserted into E. coli to be overexpressed for 
purification. Not only is the CHAPK lysin highly effective 
against MRSA, but it can disperse S. aureus biofilms[72]. 
Efforts to optimize lysins through bioengineering 
have yielded some promising results. Yang et al[73] 
produced a novel chimeric lysin, by combining the 
active site of a lysin with a cell wall binding domain, 
that was capable of saving mice challenged with MRSA 
bacteremia. Research on chimeric lysin enzymes is 
still in the early stages, but some of these modified 
lysins have also been shown to prevent death from S. 
pneumoniae bacteremia[74] and prevent development 
of methicillin-sensitive S. aureus endophthalmitis in 
a mouse model[75]. Since lysins act by enzymatically 
cleaving the bacterial cell wall, they are inherently less 
effective against gram-negative bacteria which have 
an impermeable lipopolysaccharide outer membrane. 
In an attempt to broaden lysin activity to target gram-
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as much of the current research on the immunological 
response to phage is limited to animal models. 
Specificity 
In stark contrast to antibiotics, phages tend to be 
specific towards both species and strain. In certain 
situations this can be a major advantage, considering 
the well-documented, collateral effects of broad-
spectrum antibiotics on commensal gut microbes, 
which are notorious for secondary outcomes such as 
antibiotic-associated diarrhea and C. difficile infection[90]. 
Other consequences of antibiotic perturbations in 
the gut microbial community include risk of asthma, 
obesity, and diabetes[91-93]. The current understanding 
of collateral damage due to phage therapy is limited, 
but, compared to antibiotics, phage therapy has 
been reported to result in less perturbation of the gut 
microbiome while still effectively reducing gut carriage 
of pathogens such as Shigella sonnei and uropathogenic 
E. coli[94,95]. 
While strain and species specificity of antibacterial 
compounds offers many advantages, it comes with a 
number of inherent constraints. By targeting a single 
pathogen, phage therapy could be less effective against 
infections such as infected burn wounds, which are 
often colonized by more than one strain of bacteria[96]. 
This can be accounted for by creating phage cocktails 
infective against a range of known pathogens, but the 
success of this approach depends on knowledge of 
which pathogens are being treated. Logistically, host 
specificity significantly impacts treatment development 
and testing, and also limits the possibility of large-
scale production and distribution, a distinct advantage 
the pros of phage therapy likely outweigh the cons in 
non-immunocompromised patients, the immunological 
response to phage may be indicative of the potential for 
an adverse reaction in immunocompromised patients, 
which could hypothetically worsen a patient's condition. 
There is currently no consensus on this possibility as 
other researchers argue it is unlikely phage therapy will 
elicit such an adverse reaction in immunocompromised 
patients[86]. 
Additional complications include the possibility 
that phage cocktails induce a state of intestinal barrier 
dysfunction, otherwise known as “leaky gut”. Tetz and 
Tetz used a mouse model to demonstrate that oral 
administration of a commercial Russian phage cocktail 
was capable of increasing intestinal permeability and 
elevating serum levels of inflammatory circulating 
immune complexes in the blood, which are associated 
with a number of pathological conditions[87]. However, 
another study observed no significant increase in 
cytokine levels in response to phage treatment[88]. The 
potential for phage therapy to disrupt normal intestinal 
barrier function would have serious implications for 
several disorders recently linked to intestinal barrier 
dysfunction such as Crohn’s disease, inflammatory bowel 
disease, and type 1 diabetes[87]. Pincus et al[89] found that 
the inflammatory response to phage was dependent on 
site of infection. Clearly, many of the safety concerns 
with phage therapy still need to be addressed. It is 
likely that the physiological response to phages also 
differs between individuals and is dependent on the 
specific phage strains used. To determine the safety of 
phage treatments in regards to human health, future 
investigations will need to focus on human clinical trials 
Table 2  Recently published findings on phage lytic enzymes
Lytic enzyme Model Target pathogens Result summary Ref.
Phage-derived 
lysins
ABgp46 In vitro MDR Acinetobacter 
baumannii, Pseudomonas 
aeruginosa, and Salmonella 
typhimurium
Cross-inoculation significantly reduced bacterial 
density
[64]
PlyF307 Murine MDR A. baumannii i.p. treatment rescued mice from lethal bacteremia [65]
Cpl-1 Murine Streptococcus pneumoniae i.p. treatment rescued mice from lethal pneumonia [66]
Cocktail of 6 
distinct lysins
In vitro and murine in 
vivo
MRSA Effective against biofilms in vitro and protected mice 
from lethal sepsis
[67]
PlyCD In vitro and ex vivo Clostridium difficile Reduced C. difficile colonization [68]
PlySs2 Murine Streptococcus pyogenes and 
MRSA
i.p. treatment reduced mortality from lethal bacteremia [69]
PlyG In vitro Bacillus anthracis Eliminated B. anthracis spores and vegetative cells [71]
Bioengineered 
chimeric lysins
CHAPK In vitro MRSA Eliminated MRSA and dispersed biofilms [72]
ClyH Murine MRSA Treatment rescued mice from bacteremia [73]
Cpl-711 Murine S. pneumoniae Treatment rescued mice from bacteremia [74]
Ply187 Murine Staphylococcus aureus Prevented bacterial endophthalmitis [75]
Artilysins Nematode gut P. aeruginosa Decolonized P. aeruginosa from gut [76]
Human keratinocytes A. baumannii Protected cells from bacterial challenge [76]
Lysin and 
antibiotic 
combination 
therapy
CF-301 Murine MRSA Lysin treatment was most effective when combined 
with vancomycin or daptomycin
[77]
MR-10 Murine Burn wound infection Lysin treatment was most effective when combined 
with  minocycline
[78]
MDR: Multi-drug-resistant; i.p.: Intraperitoneal injection; MRSA: Methicillin-resistant S. aureus.
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pathogen P. aeruginosa not only prevented additional 
biofilm formation by the pathogen but also degraded 
existing biofilm. Phage treatments have eliminated 
biofilms formed by L. monocytogenes, P. aeruginosa, 
and Staphylococcus epidermidis on the surface of 
medical devices[22]. These findings are highly relevant 
to the problem of persistent infections caused by 
implanted medical devices such as catheters, lenses, 
and prostheses where biofilm formation is common. 
Phage cocktails 
Due to the massive diversity of environmental phages, 
designing a phage cocktail is substantially more 
complicated than designing a regimen for combination 
antibiotic therapy. Composition of the phage cocktail 
is critical for the success of phage therapy. Factors 
in the construction of a phage cocktail are beyond 
the scope of this review and have been thoroughly 
discussed elsewhere[105], but one of the major logistical 
challenges is whether to approach phage therapy with 
a standardized or a customized cocktail. Customizing 
phage cocktails to each infection is time consuming 
and costly but, on the other end of the spectrum, a 
“one-size-fits-all” approach may not provide the strain 
specificity required for favorable clinical outcomes[105]. 
Other considerations are the collateral effects of phages 
on the indigenous microbiota, a topic that has not 
yet been fully explored[88,94,95]. In cocktail design, one 
must also take into account phage lifecycle. Lysogenic 
phages appear to be very common in the indigenous 
gut microbiota, with prophages comprising the majority 
of the gut virome[25]. Some therapeutically promising 
lysogenic phages effectively silence virulence genes 
in pathogenic bacteria or provide genes for short 
chain fatty acid metabolism, whereas other lysogenic 
phages supplement genes for virulence and antibiotic 
resistance[29,30,106]. 
Antibiotic resistance genes have been collected from 
the phage fraction of DNA in wastewater and have been 
reported to persist longer in phages than in bacteria[107]. 
Antibiotic resistance genes are also present in the phage 
fraction of human fecal samples and antibiotic treatment 
in mice enriches the abundance of phage-encoded 
antibiotic resistance genes, indicating a possible role for 
phages as a reservoir for antibiotic resistance genes[30-32]. 
The hypothetical potential for lysogenic phages to 
complicate existing infections through the horizontal 
transfer of antibiotic resistance genes to infectious 
bacteria largely excludes them from consideration 
for most phage cocktails. Yet, Regeimbal et al[106] 
demonstrated the possibility for an innovative application 
of lysogenic phages by designing an “intelligent” 5 
phage cocktail that eliminated A. baumannii skin wound 
infection in a mouse model. This intelligent phage 
cocktail was composed of 4 phages that were incapable 
of lysing the A. baumannii host and 1 phage that only 
inhibited growth in vitro. The growth-inhibiting phage 
targeted capsulated A. baumannii, selecting for the loss 
of the capsule. The removal of the capsule, a known 
of broad-spectrum antibiotics. Bourdin et al[15] cross-
inoculated phages from 2 distinct geographic regions 
(Mexico and Bangladesh) against diarrhea-associated 
E. coli from the same regions and found that phage 
showed high strain specificity to the E. coli of their 
indigenous region. In a randomized clinical trial, Sarker 
et al[60] administered a commonly used Russian E. 
coli phage cocktail to a cohort of 120 Bangladeshi chil-
dren with microbiologically-proven enterotoxogenic 
E. coli diarrhea. No improvement of clinical outcome 
was observed in patients receiving the phage cocktail 
compared to placebo[60]. These findings are in line with 
the in vitro work that suggests phage cocktails are 
better adapted to local bacterial populations[15], and 
bacterial host range can be restricted both spatially and 
temporally[97]. In an in vitro cross-inoculation of a phage 
cocktail against shiga toxin-producing E. coli O157:
H7, lysis occurred in isolates of both human and bovine 
origin, which suggests a potential for regional phage 
cocktails for both clinical and agricultural settings[98]. 
Latz et al[99] found that phages targeting antibiotic-
resistant bacteria are more likely to be found within 
the environment of the infected patient, which, in this 
case, was the hospital effluent where the antibiotic-
resistant bacteria were isolated. Regional specificity may 
therefore be advantageous when looking for phages 
that target specific bacterial strains. 
Regional specificity may be helpful in finding pha-
ges with the greatest infectivity towards the target 
pathogen, this would especially benefit regions with 
limited access to antibiotics. Together, the mounting 
evidence for the local adaptivity of phage suggests that 
regulatory pipelines must also be rapidly adaptable 
(i.e., allowing for the replacement or addition of phages 
into cocktails without requiring further clinical trials) for 
phage therapy to work on a global scale. 
Biofilm penetration 
Antibiotic therapy is highly effective with planktonic 
bacteria, such as V. cholerae and Yersinia pestis, yet is 
limited in treating biofilm-based bacterial infection[100]. 
Phages, however, are equipped with enzymes (e.g., 
EPS depolymerase) on the exterior of the capsid that 
degrade the extracellular polymeric substances (EPS) 
and disperse bacterial biofilms, allowing the phage to 
access bacteria embedded within the EPS matrix[83]. 
The phage progeny released upon completion of the lytic 
cycle propagate the dispersal of the biofilm through the 
removal of biofilm-embedded bacteria in subsequent 
layers[83,101]. In order to penetrate dense biofilms, high 
doses of antibiotics are typically required to observe 
any inhibition of bacterial growth, yet complete 
eradication is rare and regrowth of colonies begins 
after the end of antibiotic treatments[102,103]. Although 
low concentrations of many antibiotics are generally 
considered non-toxic, high concentrations can result 
in tissue toxicity[83]. Gabisoniya et al[104] at the Eliava 
Institute of Bacteriophages in Tbilisi, Georgia found 
that the application of phages on in vitro colonies of the 
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virulence factor, decreased the virulence of the bacterium 
and made it susceptible to lysis from the 4 additional 
phages[106]. This type of cocktail design represents the 
beginning of novel treatment options for eliminating 
bacterial infections that are resistant to conventional 
treatment. Lysogenic phages have many intriguing 
properties that may be useful for this type of in situ 
manipulation of individual bacterium, and potentially the 
human gut microbiome metagenome[108], but first much 
more needs to be known about the role of lysogenic 
phages in the human gut phageome for this to be done 
safely and effectively. 
CONCLUSION 
The available literature on the use of phages and phage-
derived proteins for combating bacterial infections, 
specifically those of multidrug-resistant bacteria, 
increasingly shows promise for the prospect of phage 
therapy as either an alternative or a supplement to 
antibiotics. However, discrepancies in recent findings 
on the immunomodulatory effects, the host range, 
and the potential for horizontal gene transfer make it 
abundantly clear that we need a better understanding 
of the interaction between phage, microbiome, and 
human host before implementing phage therapy 
on a large scale. Phage lysins may thus be a much 
more practical therapeutic tool for their decreased 
immunological potential, among other reasons such 
as ease of production, purification, and storage. 
Despite the promising preliminary findings on phage 
and phage-derived lytic proteins, it is more than likely 
that no panacea for antibiotic-resistant infections will 
arise. The increased efficacy of antibacterial agents 
when used in conjunction implies that therapy using 
some combination of phage, phage-derived lytic 
proteins, bioengineered phage, and/or antibiotics will 
be necessary for addressing the growing problem of 
antibiotic-resistant infections. 
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